Kornimate/medical-research-clean huggingface dataset:
chemoradiotherapy sequenced radical surgery for colorectal cancer with palnm

Conditions: Colorectal Neoplasms Malignant; Lymph Node Excision; Chemoradiotherapy

Summary: in left-sided colon and rectal cancer, the occurrence of synchronous para-aortic lymph node metastasis is rare, with the incidence of being approximate 1-2%. currently, there has been no standard treatment strategy for this situation. the present trial is designed to evaluate the safety and efficacy of para-aortic lymph node dissection for left-sided colon and rectal cancer with synchronous para-aortic lymph node metastasis


Eligibility criteria:
inclusion criteria: * age at enrollment is ≥ 18 and ≤ 75 years * ecog ps 0-1 * histologically confirmed left-sided colon and rectal carcinoma * synchronous para-aortic lymph node metastases confirmed by pet-ct, and located below the level of renal veins and above the bifurcation of iliac artery * patients potential to receive surgery and achieve no evidence of disease (ned) * able to tolerate surgery * providing written informed consent exclusion criteria: * local invasion or distant metastasis other than para-aoritc lymph nodes * history of other malignant tumor * coupled with severe systematic diseases (recent myocardial infarction, cardiomyopathy, or acute pulmonary infection) * emergency surgery
does radiofrequency ablation of the articular nerves of the knee prior to total knee replacement improve pain outcomes

Conditions: Arthroplasty, Replacement, Knee

Summary: more than 300,000 total knee joint replacement surgeries are performed per year in the united states and safe, effective management of post-operative pain in these patients, often elderly, deconditioned, obese, or with co-morbid diseases like sleep apnea, can be challenging and often require a multidisciplinary, multimodal approach. opiates have been a mainstay of treatment in the post-operative period with varying degrees of success and complications. inadequately controlled postoperative pain is not uncommon. poorly controlled pain inhibits early mobilization and hinders post-operative physical therapy. a new paradigm for treating post-operative pain following total knee replacement may be the use of cooled radiofrequency ablation (c-rfa) of the articular sensory nerve supply of the knee capsule prior to surgery, to desensitize the knee by blocking sensory afferents to the anterior capsule and thereby decrease post-operative pain. there are several publications that have demonstrated the use of rfa in patients with chronic knee pain from osteoarthritis however the use of rfa in the preoperative management of pain in patients undergoing total knee joint replacement has not been investigated. the aim of this study is to determine if patients undergoing unilateral total knee replacement obtain any post-operative pain relieving benefits from c-rfa of the articular sensory nerve supply when performed prior to surgery, as compared to sham controls who receive only local anesthetic injections of these same nerves without the benefit of ablation treatment.


Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee scheduled to undergo their first unilateral knee joint replacement * willingness to undergo fluoroscopy-guided c-rfa or sham treatment exclusion criteria: * pregnancy, * severe cardiac/pulmonary compromise, * acute illness/infection, * coagulopathy * bleeding disorder, * allergic reactions, * contraindications to a local anesthetic

Keywords: total knee replacement, replacement of the knee joint,
study of bbp-418 in patients with lgmd2i

Conditions: LGMD2I

Summary: bbp-418 is being developed for the treatment of patients with limb-girdle muscular dystrophy type 2i (lgmd2i). this is an open label study to determine the safety and tolerability of ascending dose levels of bbp-418 in the treatment of ambulatory and non-ambulatory patients with lgmd2i for which no approved therapy currently exists.

this is an open label study in ambulatory and non-ambulatory subjects with lgmd2i (also known as lgmd r9) previously enrolled in the natural history study mlb-01-001. this is a study to determine the safety and tolerability of ascending dose levels of bbp-418 in those subjects.

Eligibility criteria:
inclusion criteria: * have a body weight \>30 kg * have a genetically confirmed diagnosis of lgmd2i and be clinically affected (defined as demonstrating clinical weakness on bedside evaluation in either a limb-girdle pattern, or in a distal extremity) * able to complete the 10-meter walk test in ≤ 12 seconds unaided ("moderate disease") or are with "severe disease"/non-ambulatory as defined by being unable to complete the 10-meter walk unaided in \>12 seconds * willing to use an adequate method of contraception from time of consent through 12 weeks after last dose * previous enrolment in the natural history study mlb-01-001 exclusion criteria: * evidence of clinically significant concomitant disease, including: * any history of a gastrointestinal condition, including surgeries, which may affect absorption after oral administration * any significant concomitant medical condition, including cardiac, pulmonary, renal, hepatic or endocrine disease other than that associated with lgmd2i * any condition other than lgmd2i requiring therapy with prescription medicine (medication for common and mild concomitant conditions may be permitted after consultation with the pi) * any other laboratory, vital sign, ecg abnormality, or clinical history or finding that, in the investigator's opinion, is likely to unfavorably alter the risk-benefit of study participation, confound study results, or interfere with study conduct or compliance * if pregnant and/or breastfeeding or planning to conceive children within the projected duration of the study through 12 weeks after the last dose of study treatment. * history of drug abuse including alcoholism within 2 years prior to consenting * use of ribose or other sugar alcohol-containing supplement within 60 days of day 1 * use of a corticosteroid within 60 days of day 1 * presence of a platelet disorder, bleeding disorder or other contraindication to muscle biopsy * actively on an experimental therapy or device or was on an experimental therapy or device within 60 days prior to day 1.

Keywords: lgmd lgmd r9 limb girdle muscular dystrophy
a safety study of xl019 in adults with myelofibrosis

Conditions: Myeloproliferative Disorders; Myelofibrosis; Polycythemia Vera; Thrombocythemia, Essential

Summary: the purpose of this study is to evaluate the safety and tolerability of xl019 in adults with myelofibrosis. xl019 is a selective inhibitor of the cytoplasmic tyrosine kinase jak2. jak2 is activated by cytokine and growth factor receptors and phosphorylates members of the stat family of inducible transcription factors. activation of the jak/stat pathway promotes cell growth and survival, and is a common feature of human tumors. jak2 is activated by mutation in the majority of patients with myelofibrosis, polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.


Eligibility criteria:
inclusion criteria: * the subject has primary myelofibrosis (pmf), post-polycythemia vera mf, or post-essential thrombocythemia mf and requires therapy, including subjects who have received prior mf-directed therapy and relapsed or subjects with refractory disease; or if newly diagnosed, then with intermediate or high risk according to the lille scoring system. * the subject is unwilling to undergo or is not a candidate for peripheral stem cell/bone marrow transplant. * the subject is ≥18 years old. * the subject has an eastern cooperative oncology group (ecog) performance status of ≤2. * the subject has adequate organ function. * the subject has the capability of understanding the informed consent document and has signed the informed consent document. * sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study. * female subjects of childbearing potential must have a negative pregnancy test at screening. * the subject has had no diagnosis of malignancy or evidence of other malignancy for 2 years prior to screening for this study (except non-melanoma skin cancer or in situ carcinoma of the cervix). exclusion criteria: * the subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within 3 months, or cardiac arrhythmias. * the subject is pregnant or breastfeeding. * the subject is known to be positive for the human immunodeficiency virus (hiv). * the subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.

Keywords: myeloproliferative disorders
effect of pulse fractions on indices on cardiovascular disease and diabetes risk factors

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to determine if whole and fractionated yellow pea flour, administered at usda recommended dosages (50 g/day), improve risk factors associated with cardiovascular disease and diabetes.


Eligibility criteria:
inclusion criteria: * bmi between 25 and 40 kg/m2 * hypercholesterolemic exclusion criteria: * smoking * use of prescription and natural lipid lowering therapies * myocardial infarction * coronary artery bypass * angina * congestive heart failure, * inflammatory bowel disease * pancreatitis * renal disease * diabetes * chronic alcohol usage (\> 2 drinks/day). * cancer * eating disorders * expending \> 4000 kcal/week through exercise

Keywords: peas cardiovascular diabetes insulin insulin resistance abdominal fat
efficacy and safety of aju-a51 in type 2 diabetes mellitus patients

Conditions: Type2 Diabetes

Summary: a multicenter, randomized, double-blind, parallel group, placebo-controlled, phase 3 study to evaluate the efficacy and safety of the combination of a51r3 and aju-a51 compared with the combination of a51r3 and a51r2 in patients with type 2 diabetes mellitus who have inadequate glycemic control with the combination of a51r3 and a51r2


Eligibility criteria:
inclusion criteria: * those who voluntarily signed the informed consent to participate in this study. * adults aged 19-75 years. * those diagnosed with type 2 diabetes mellitus. * 7% ≤ hba1c ≤ 10.5% * fpg ≤ 270 mg/dl * bmi ≤ 40 kg/㎡ * subjects able to understand the study, comply with study procedures, and attend all scheduled visits. exclusion criteria: * those who suffered from acute or chronic metabolic acidosis, lactic acidosis and diabetic ketoacidosis. * those who had genetic disorders such as galactose intolerance, lapp lactose deficiency, or glucose-galactose malabsorption. * those with heart failure (nyha class ii\~iv) or who had suffered from heart failure. * those with a history of malignant tumor within 5 years * those who have a clinically significant liver disease * those who have a clinically significant renal disease * sbp \> 180 mmhg or dbp \> 110 mmhg * those who had allergic reaction to main ingredients or components of the investigational products. * patients planning to become pregnant or of childbearing potential, but not using any recognized contraceptive method * females who are pregnant or breastfeeding. * ast or alt ≥ lrn\*3 * tg ≥ 500 mg/dl
lifestyle changes reducing type 2 diabetes risk among arab canadian muslim women.

Conditions: Lifestyle Risk Reduction; Type2 Diabetes

Summary: aim: the purpose was to investigate whether modifiable risk factors for type 2 diabetes can be reduced by an intensive healthy lifestyle intervention designed for arab muslim women. methods: women were assigned randomly to either an exercise and nutrition group (eng) or a control group (cg). the eng attended a women-only supervised exercise program that presented arabic music and traditional lebanese dabka steps three times/week in the mosque gym for 12 weeks. a nutritionist was available one hour/week for nutrition education. the cg followed their typical day.

women were assigned randomly using a computer-generated random numbers table to either an exercise and nutrition group (eng) or a control group (cg). the women received step-by-step instructions on how to complete a consecutive 3-day food record (including two week-days and one weekend day) and an exercise log for 7 days using a pedometer (yamax sw-200 digi-walker) to determine steps/day. the information and instruction were delivered to the women in english or arabic. body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively. women came to the lab after a 12 hour fast and a blood sample was drawn. waist and hip measurements were taken along with resting blood pressure. estimated fitness levels was measured by a trained kinesiologist using a step test (siconolfi et al. 1985). all baseline measurements, including the 3-day food intake record and the 7-day pedometer step count log were repeated at the end of the 12-week intervention in both groups. the eng group attended a supervised women-only exercise program that presented arabic music and traditional dance steps (the lebanese dabka) three times a week in the london muslim mosque gym and received nutrition education over the 12 weeks, one session per week.

Eligibility criteria:
inclusion criteria: * family history of type 2 diabetes (at least one parent), * overweight or obese, * been in canada more than 10 years, * mild hypertension, * impaired glucose tolerance, or previous gestational diabetes (including giving birth to babies 4.0 kg or more), * a sedentary lifestyle exclusion criteria: * uncontrolled hypertension, * unstable angina, * pulmonary and metabolic disease, * severe arthritis or rheumatologic problems, * already engaged in regular exercise training, * pregnancy, * menopause, * already enrolled in a clinical research trial

Keywords: type 2 diabetes risk reduction lifestyle intervention arab canadian muslim women
efficacy and safety of hydroxychloroquine and azithromycin for the treatment of ambulatory patients with mild covid-19

Conditions: Covid-19

Summary: this is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg bid on d1 and 400 mg/day on d2 to d7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory covid-19 patients.

this is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg bid on d1 and 400 mg/day on d2 to d7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory covid-19 patients. we aim to demonstrate decrease in hospital related complications among ambulatory patients with mild covid-19 by treating them with hcq and azt on top of standard care compared to patients who receive standard care only. ambulatory patients on day 3 of symptoms and with confirmed diagnosis of covid-19 will receive the treatment. patients that do not fulfill the inclusion/exclusion criteria or that is not willing to participate in the study will be invited to consent the use of their data as part of a "control" group.

Eligibility criteria:
inclusion criteria: 1. informed consent from patient or legal representative. 2. male or female, and: 1. aged ≥ 70 years; or 2. aged \< 70 with associated risk factors (chronic obstructive pulmonary disease; heart failure, immunosuppressed, obesity (bmi ≥ 35) uncontrolled diabetes and uncontrolled systemic arterial hypertension) 3. one or more mild symptoms characteristic of covid-19 for 3 days, such as fever, cough and signs of respiratory distress, which do not require hospitalization. exclusion criteria: 1. participating in another rct in the past 12 months; 2. known allergy to hcq or chloroquine 3. any contraindication to htc or azt, including retinopathy and prolonged qt, 4. severely reduced lv function 5. severely reduced renal function; 6. pregnancy or breast feeding 7. any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of the investigational products
role of radiotherapy following oesophageal stenting in cancer

Conditions: Oesophageal Cancer

Summary: to assess the benefits of oesophageal stenting and external beam radiotherapy over oesophageal stenting alone in patients with inoperable oesophageal cancer

a majority of patients with oesophageal cancer present with inoperable disease and require rapid and long lasting palliation of dysphagia. study aim: to compare dysphagia relief in patients treated with oesophageal stenting and external beam radiotherapy (ebrt), versus oesophageal stenting alone and to assess overall survival, treatment related complications, and quality of life in the two groups. patients and methods: patients with inoperable oesophageal cancer with high grade dysphagia to be randomised to receive oesophageal stenting alone (group i), versus a combination of stenting followed by ebrt (group ii). dysphagia relief, treatment related complications, overall survival, and quality of life to be assessed in the two groups.

Eligibility criteria:
inclusion criteria: * oesophageal cancer patients with locally advanced unresectable cancer (such as invasion of tracheo-bronchial tree, aorta, pulmonary vascular structures, etc), * metastatic disease, and co-morbid conditions precluding major surgical procedure (such as severe cardiopulmonary, hepatic and renal diseases) with grade 3 and 4 dysphagia, were included in the trial. exclusion criteria: * patients with carcinoma of the cervical oesophagus and those who had already received prior radiotherapy, chemotherapy, or any other modality of treatment were excluded

Keywords: palliation inoperable oesophageal cancer
hand dermatitis in the care and hospital staff

Conditions: Hand Dermatoses

Summary: study of the prevalence and risk factors of occupational dermatitis in the hands of caregivers and hospital staff of the brest chru.

monocentric cross-sectional descriptive study by anonymous self-questionnaire designed to evaluate among caregivers and agents hospitals of the chru de brest: * the prevalence of occupational hands dermatitis * the risk factors for hands dermatitis * the clinical description of the hands dermatitis * the rates of dermatitis according to hand hygiene practices (soap, hydro-alcoholic solution, associations of the two, wearing gloves ...) * the changes in the hygiene practices of caregivers and hospital staff of the university hospital caused by hand dermatitis. * the professional and socio-economic impact of these hands dermatitis * the evaluation of the use of care for these hands dermatitis. * the assessment of the association of hand dermatitis with a personal or family atopic history.

Eligibility criteria:
inclusion criteria: * any caregiver, hospital staff or staff involved incare or stretchering of chu patients returning tosocioprofessional categories cited in the questionnaire. * major person * participation agreement exclusion criteria: * minor person. * administrative services staff, restaurant staff,technical staff * refusal to participate

Keywords: hand dermatoses hand dermatitis occupationnal caregivers hand hygiene
acupuncture and hot flashes

Conditions: Hot Flashes

Summary: methods: 103 participants, after being randomized to medical versus sham acupuncture received bi-weekly treatments for 5 weeks, after a baseline assessment week. they were then followed for an additional 7 weeks. participants completed daily hot flash questionnaires, which formed the basis for analysis.


Eligibility criteria:
participants eligible for this study were females aged 45 to 59 with a reported average of ¡ý 5 hot flashes a day
exercise exposure data collection in patients undergoing tumor molecular profiling

Conditions: Cancer; Carcinoma

Summary: this study will recruit approximately 5,000 patients with histologically confirmed cancer who have successfully completed msk-impact panel testing and collect information about tumor genetic results and patient exercise behavior history. the purpose of the study is to create a registry to collect exercise behavior history in patients who had impact genetic panel testing on protocol irb #12-245 "genomic profiling in cancer patients", irb #06-107 "storage and research use of human biospecimens," or irb #09-141 "collection of human biological specimens from patients for research studies." the investigators want to find a way to create an exercise database. this database will collect information about tumor genetic results and patient exercise behavior history.


Eligibility criteria:
cohort 1: impact cohort inclusion criteria: * histologically-confirmed cancer. * impact testing with completed genomic profile completed within three years of initial recruitment approach * registered to memorial sloan kettering cancer center protocol irb# 12-245 and/or irb #06-107 and/or irb # 09-141 * ≥ 18 years of age * ecog performance status of 0 or 1 exclusion criteria: * unable to speak and read english * not willing to provide informed consent

Keywords: histologically confirmed cancer impact testing 17-327
the pharmaco-genetic and brain mechanisms associated with cannabis- induced psychosis

Conditions: Cannabis Dependence; Psychosis

Summary: there is growing evidence of high rates of substance use disorders among individuals with psychotic disorders especially in young people with predisposition for psychosis. there is some genetic evidence that carriers of the valine158 allele of the catechol-o-methyltransferase (comt) gene had increased risk to exhibit psychotic symptoms and to develop schizophrenia if they used cannabis by the age of 18. it was also shown that carriers of the comt val/val genotype were most sensitive to thc-induced psychotic experiences but this was conditional on pre-existing susceptibility to psychosis. the investigators propose to use brain-imaging and molecular genetics to investigate whether genetic factors may contribute to the thc-induced dopamine release and possibly to cannabis- induced psychosis.

genetic association study will be performed in 100 young cannabis users (age 18-26 years) for genes that are related to the neurotransmitters dopamine (d2, dat, comt), gaba, glutamate and the cannabinoid receptor cb1. out of this cohort, 24 male subjects without history of cannabis or drug-induced psychosis will undergo brain imaging procedure in order to measure thc-induced dopamine release using \[11c\] raclopride in pet imaging. carriers of high activity comt158val allele are expected to show higher meso-limbic da release than carriers of low activity comt 158met homozygotes and after smoking a cigarette with thc which in turn are thought to underlie the risk for thc-induced psychotic symptoms. the aim of the present study is to evaluate the relationship between the comt genotype and cannabis-induced meso-limbic dopamine release as measured by d2 occupancy. in addition, the association between predisposition to psychosis, age of onset of cannabis dependence, and genotype of comt and other neurotransmitters-related genes will be evaluated. such finding could provide novel pharmaco-genetic explanation for the psychogenic effects of cannabis in vulnerable individuals.

Eligibility criteria:
inclusion criteria: * age 18-26 meeting dsm-iv-tr (american psychiatric association, 1994) diagnosis of thc dependence will be recruited from the general population by advertisement in the newspapers. exclusion criteria: * dependence on other substances or alcoholism * a history of cns disease * a history of infection that might affect cns (hiv, syphilis, cytomegalovirus, herpes) * a history of head injury with loss of consciousness and pregnancy

Keywords: cannabis thc comt psychosis d2